Author Interviews, Johns Hopkins, NEJM / 13.02.2014
Restless Legs Syndrome: Lyrica Found Superior to Mirapex
MedicalResearch.com Interview with:
Dr. Richard P. Allen
Department of Neurology
Johns Hopkins University
Baltimore, MD 21224,
MedicalResearch.com: What are the main findings of the study?
Dr. Allen: This study should serve to change medical practice by reducing use of pramipexole and ropinirole to avoid the insidious worsening of restless legs syndrome that occurs for many on these drugs.
Pramipexole (Mirapex) a medication that mimics dopamine in the brain in usual therapeutic doses for treatment of restless legs syndrome (RLS) works at first but over time one year makes the disease worse for up to 9% of the patients on 0.5 mg a day.
Pregabalin (Lyrica) an anti-convulsant and pain drug that works on a calcium channel in the brain in therapeutic dose for RLS (300 mg a day) does not make the disease worse (There is some natural progression of the disease shown to occur fro 1 - 2% or patients over a year.. seen in this study).
Pregabalin is in the short run as effective as pramipexole (over 12 weeks) and in the long run over 52 weeks more effective.
These results confirm what had been expected that the dopamine drug pramipexole makes worse Restless Legs Syndrome while a drug not directly acting on the dopamine system does NOT make restless legs syndrome worse.

























